1
|
Cui M, Göbel V, Zhang H. Uncovering the 'sphinx' of sphingosine 1-phosphate signalling: from cellular events to organ morphogenesis. Biol Rev Camb Philos Soc 2021; 97:251-272. [PMID: 34585505 PMCID: PMC9292677 DOI: 10.1111/brv.12798] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Revised: 09/11/2021] [Accepted: 09/16/2021] [Indexed: 11/02/2022]
Abstract
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabolite, functioning as a signalling molecule in diverse cellular processes. Over the past few decades, studies of S1P signalling have revealed that the physiological activity of S1P largely depends on S1P metabolizing enzymes, transporters and receptors on the plasma membrane, as well as on the intracellular proteins that S1P binds directly to. In addition to its roles in cancer signalling, immunity and inflammation, a large body of evidence has identified a close link of S1P signalling with organ morphogenesis. Here we discuss the vital role of S1P signalling in orchestrating various cellular events during organ morphogenesis through analysing each component along the extracellular and intracellular S1P signalling axes. For each component, we review advances in our understanding of S1P signalling and function from the upstream regulators to the downstream effectors and from cellular behaviours to tissue organization, primarily in the context of morphogenetic mechanisms. S1P-mediated vesicular trafficking is also discussed as a function independent of its signalling function. A picture emerges that reveals a multifaceted role of S1P-dependent pathways in the development and maintenance of organ structure and function.
Collapse
Affiliation(s)
- Mengqiao Cui
- Centre of Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, 999078, China
| | - Verena Göbel
- Mucosal Immunology and Biology Research Center, Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, U.S.A
| | - Hongjie Zhang
- Centre of Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, 999078, China.,MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR, 999078, China
| |
Collapse
|
2
|
Pulli I, Asghar MY, Kemppainen K, Törnquist K. Sphingolipid-mediated calcium signaling and its pathological effects. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2018; 1865:1668-1677. [DOI: 10.1016/j.bbamcr.2018.04.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 04/17/2018] [Accepted: 04/23/2018] [Indexed: 12/15/2022]
|
3
|
Asghar MY, Magnusson M, Kemppainen K, Sukumaran P, Löf C, Pulli I, Kalhori V, Törnquist K. Transient Receptor Potential Canonical 1 (TRPC1) Channels as Regulators of Sphingolipid and VEGF Receptor Expression: IMPLICATIONS FOR THYROID CANCER CELL MIGRATION AND PROLIFERATION. J Biol Chem 2015; 290:16116-31. [PMID: 25971967 DOI: 10.1074/jbc.m115.643668] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Indexed: 01/09/2023] Open
Abstract
The identity of calcium channels in the thyroid is unclear. In human follicular thyroid ML-1 cancer cells, sphingolipid sphingosine 1-phosphate (S1P), through S1P receptors 1 and 3 (S1P1/S1P3), and VEGF receptor 2 (VEGFR2) stimulates migration. We show that human thyroid cells express several forms of transient receptor potential canonical (TRPC) channels, including TRPC1. In TRPC1 knockdown (TRPC1-KD) ML-1 cells, the basal and S1P-evoked invasion and migration was attenuated. Furthermore, the expression of S1P3 and VEGFR2 was significantly down-regulated. Transfecting wild-type ML-1 cells with a nonconducting TRPC1 mutant decreased S1P3 and VEGFR2 expression. In TRPC1-KD cells, receptor-operated calcium entry was decreased. To investigate whether the decreased receptor expression was due to attenuated calcium entry, cells were incubated with the calcium chelator BAPTA-AM (1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid). In these cells, and in cells where calmodulin and calmodulin-dependent kinase were blocked pharmacologically, S1P3 and VEGFR2 expression was decreased. In TRPC1-KD cells, both hypoxia-inducible factor 1α expression and the secretion and activity of MMP2 and MMP9 were attenuated, and proliferation was decreased in TRPC1-KD cells. This was due to a prolonged G1 phase of the cell cycle, a significant increase in the expression of the cyclin-dependent kinase inhibitors p21 and p27, and a decrease in the expression of cyclin D2, cyclin D3, and CDK6. Transfecting TRPC1 to TRPC1-KD cells rescued receptor expression, migration, and proliferation. Thus, the expression of S1P3 and VEGFR2 is mediated by a calcium-dependent mechanism. TRPC1 has a crucial role in this process. This regulation is important for the invasion, migration, and proliferation of thyroid cancer cells.
Collapse
Affiliation(s)
| | - Melissa Magnusson
- From the Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland
| | - Kati Kemppainen
- From the Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland
| | - Pramod Sukumaran
- the Department of Biochemistry and Molecular Biology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota 58201
| | - Christoffer Löf
- Department of Physiology, Institute of Biomedicine, University of Turku, 20520 Turku, Finland, and
| | - Ilari Pulli
- From the Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland
| | - Veronica Kalhori
- From the Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland, the Minerva Foundation Institute for Medical Research, Biomedicum Helsinki, 00270 Helsinki, Finland
| | - Kid Törnquist
- From the Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland, the Minerva Foundation Institute for Medical Research, Biomedicum Helsinki, 00270 Helsinki, Finland
| |
Collapse
|
4
|
Pulli I, Blom T, Löf C, Magnusson M, Rimessi A, Pinton P, Törnquist K. A novel chimeric aequorin fused with caveolin-1 reveals a sphingosine kinase 1-regulated Ca²⁺ microdomain in the caveolar compartment. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2015; 1853:2173-82. [PMID: 25892494 DOI: 10.1016/j.bbamcr.2015.04.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 03/13/2015] [Accepted: 04/07/2015] [Indexed: 11/18/2022]
Abstract
Caveolae are plasma membrane invaginations enriched in sterols and sphingolipids. Sphingosine kinase 1 (SK1) is an oncogenic protein that converts sphingosine to sphingosine 1-phosphate (S1P), which is a messenger molecule involved in calcium signaling. Caveolae contain calcium responsive proteins, but the effects of SK1 or S1P on caveolar calcium signaling have not been investigated. We generated a Caveolin-1-Aequorin fusion protein (Cav1-Aeq) that can be employed for monitoring the local calcium concentration at the caveolae ([Ca²⁺]cav). In HeLa cells, Cav1-Aeq reported different [Ca²⁺] as compared to the plasma membrane [Ca²⁺] in general (reported by SNAP25-Aeq) or as compared to the cytosolic [Ca²⁺] (reported by cyt-Aeq). The Ca²⁺ signals detected by Cav1-Aeq were significantly attenuated when the caveolar structures were disrupted by methyl-β-cyclodextrin, suggesting that the caveolae are specific targets for Ca²⁺ signaling. HeLa cells overexpressing SK1 showed increased [Ca²⁺]cav during histamine-induced Ca²⁺ mobilization in the absence of extracellular Ca²⁺ as well as during receptor-operated Ca²⁺ entry (ROCE). The SK1-induced increase in [Ca²⁺]cav during ROCE was reverted by S1P receptor antagonists. In accordance, pharmacologic inhibition of SK1 reduced the [Ca²⁺]cav during ROCE. S1P treatment stimulated the [Ca²⁺]cav upon ROCE. The Ca²⁺ responses at the plasma membrane in general were not affected by SK1 expression. In summary, our results show that SK1/S1P-signaling regulates Ca²⁺ signals at the caveolae. This article is part of a Special Issue entitled: 13th European Symposium on Calcium.
Collapse
Affiliation(s)
- Ilari Pulli
- Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland
| | - Tomas Blom
- University Of Helsinki, 00014 Helsinki, Finland
| | - Christoffer Löf
- University Of Turku, Department of Physiology, Institute of Biomedicine, Kiinamyllynkatu 10, 20520 Turku, Finland
| | | | - Alessandro Rimessi
- University of Ferrara, Dept. of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), 44121 Ferrara, Italy
| | - Paolo Pinton
- University of Ferrara, Dept. of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), 44121 Ferrara, Italy
| | - Kid Törnquist
- Åbo Akademi University, Tykistökatu 6A, 20520 Turku, Finland; Minerva Foundation Institute For Medical Research, Biomedicum Helsinki, 00270 Helsinki, Finland.
| |
Collapse
|
5
|
Wilson PC, Fitzgibbon WR, Garrett SM, Jaffa AA, Luttrell LM, Brands MW, El-Shewy HM. Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel. Mol Endocrinol 2015; 29:896-908. [PMID: 25871850 DOI: 10.1210/me.2014-1388] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Angiotensin II (AngII) plays a critical role in the regulation of vascular tone and blood pressure mainly via regulation of Ca(2+) mobilization. Several reports have implicated sphingosine kinase 1 (SK1)/sphingosine 1-phosphate (S1P) in the mobilization of intracellular Ca(2+) through a yet-undefined mechanism. Here we demonstrate that AngII-induces biphasic calcium entry in vascular smooth muscle cells, consisting of an immediate peak due to inositol tris-phosphate-dependent release of intracellular calcium, followed by a sustained transmembrane Ca(2+) influx through store-operated calcium channels (SOCs). Inhibition of SK1 attenuates the second phase of transmembrane Ca(2+) influx, suggesting a role for SK1 in AngII-dependent activation of SOC. Intracellular S1P triggers SOC-dependent Ca(2+) influx independent of S1P receptors, whereas external application of S1P stimulated S1P receptor-dependent Ca(2+) influx that is insensitive to inhibitors of SOCs, suggesting that the SK1/S1P axis regulates store-operated calcium entry via intracellular rather than extracellular actions. Genetic deletion of SK1 significantly inhibits both the acute hypertensive response to AngII in anaesthetized SK1 knockout mice and the sustained hypertensive response to continuous infusion of AngII in conscious animals. Collectively these data implicate SK1 as the missing link that connects the angiotensin AT1A receptor to transmembrane Ca(2+) influx and identify SOCs as a potential intracellular target for SK1.
Collapse
Affiliation(s)
- Parker C Wilson
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| | - Wayne R Fitzgibbon
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| | - Sara M Garrett
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| | - Ayad A Jaffa
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| | - Louis M Luttrell
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| | - Michael W Brands
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| | - Hesham M El-Shewy
- Department of Pathology (P.C.W.), Yale-New Haven Hospital, New Haven, Connecticut 06510; Departments of Medicine (W.R.F., S.M.G., A.A.J., L.M.L., H.M.E.) and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina 29425; Department of Research Service (L.M.L.), Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29401; Department of Physiology (M.W.B.), Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia 30912; and Department of Biochemistry and Molecular Genetics (A.A.J.), Faculty of Medicine, American University of Beirut, Beirut, Lebanon 113-6044
| |
Collapse
|
6
|
Flores J, Rito Y, Torres G, Jung H, Treviño-Frenk I, Corona T. Hypothyroidism in multiple sclerosis patient during fingolimod treatment. J Neurol Sci 2015; 348:272-3. [PMID: 25491264 DOI: 10.1016/j.jns.2014.11.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Revised: 10/28/2014] [Accepted: 11/04/2014] [Indexed: 10/24/2022]
Affiliation(s)
- J Flores
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - Y Rito
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
| | - G Torres
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - H Jung
- Laboratory of Neuropharmacology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - I Treviño-Frenk
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - T Corona
- Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| |
Collapse
|
7
|
Yagoub D, Wilkins MR, Lay AJ, Kaczorowski DC, Hatoum D, Bajan S, Hutvagner G, Lai JH, Wu W, Martiniello-Wilks R, Xia P, McGowan EM. Sphingosine kinase 1 isoform-specific interactions in breast cancer. Mol Endocrinol 2014; 28:1899-915. [PMID: 25216046 DOI: 10.1210/me.2013-1423] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Sphingosine kinase 1 (SK1) is a signaling enzyme that catalyzes the formation of sphingosine-1-phosphate. Overexpression of SK1 is causally associated with breast cancer progression and resistance to therapy. SK1 inhibitors are currently being investigated as promising breast cancer therapies. Two major transcriptional isoforms, SK143 kDa and SK151 kDa, have been identified; however, the 51 kDa variant is predominant in breast cancer cells. No studies have investigated the protein-protein interactions of the 51 kDa isoform and whether the two SK1 isoforms differ significantly in their interactions. Seeking an understanding of the regulation and role of SK1, we used a triple-labeling stable isotope labeling by amino acids in cell culture-based approach to identify SK1-interacting proteins common and unique to both isoforms. Of approximately 850 quantified proteins in SK1 immunoprecipitates, a high-confidence list of 30 protein interactions with each SK1 isoform was generated via a meta-analysis of multiple experimental replicates. Many of the novel identified SK1 interaction partners such as supervillin, drebrin, and the myristoylated alanine-rich C-kinase substrate-related protein supported and highlighted previously implicated roles of SK1 in breast cancer cell migration, adhesion, and cytoskeletal remodeling. Of these interactions, several were found to be exclusive to the 43 kDa isoform of SK1, including the protein phosphatase 2A, a previously identified SK1-interacting protein. Other proteins such as allograft inflammatory factor 1-like protein, the latent-transforming growth factor β-binding protein, and dipeptidyl peptidase 2 were found to associate exclusively with the 51 kDa isoform of SK1. In this report, we have identified common and isoform-specific SK1-interacting partners that provide insight into the molecular mechanisms that drive SK1-mediated oncogenicity.
Collapse
Affiliation(s)
- Daniel Yagoub
- School of Biotechnology and Biomolecular Sciences (D.Y., M.R.W.), University of New South Wales, Sydney 2052, Australia; Centenary Institute (D.Y., A.L., D.G.K., P.X., E.M.M.), Sydney 2042, Australia; Translational Cancer Research Group (D.H., R.M.-W., E.M.M.), Faculty of Science, School of Medical and Molecular Biosciences, and Faculty of Engineering and Information Technology (S.B., G.H.), University of Technology Sydney, Sydney, New South Wales 2007, Australia; Department of Biochemistry (J.H.L., W.W.), Tufts University School of Medicine, Boston, Massachusetts 02111; Shanghai Medical School (P.X.), Fudan University, 200433 Shanghai, People's Republic of China; and Sydney Medical School (E.M.M.), The University of Sydney, Sydney 2006, Australia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Törnquist K. Sphingosine 1-phosphate, sphingosine kinase and autocrine calcium signalling in thyroid cells. Acta Physiol (Oxf) 2012; 204:151-7. [PMID: 21338471 DOI: 10.1111/j.1748-1716.2011.02265.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In many cell types metabolites of sphingomyelin have a profound role in cellular signalling. One particular field where these derivatives have obtained a crucial role is calcium signalling. This is an interesting aspect on how lipids may wield their physiological role, as calcium is probably one of the most versatile signalling molecules in the cell, and modulation of calcium signalling may have profound effects on cellular physiology. In this review we discuss a novel aspect of sphingolipid signalling, i.e. the autocrine role of sphingosine 1-phosphate (S1P) in regulating calcium entry in thyroid cells. Although many investigations have highlighted the importance of S1P as a regulator of both calcium release from the endoplasmic reticulum and calcium entry through plasma membrane channels, the autocrine mechanism presented here introduces a new aspect of S1P signalling in thyroid cells. This mechanism may be physiologically relevant in many other cell types, including cancer cells.
Collapse
Affiliation(s)
- K Törnquist
- Department of Biosciences, Åbo Akademi University, Turku, Helsinki, Finland.
| |
Collapse
|
9
|
Kukkonen JP. A ménage à trois made in heaven: G-protein-coupled receptors, lipids and TRP channels. Cell Calcium 2011; 50:9-26. [DOI: 10.1016/j.ceca.2011.04.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Revised: 04/21/2011] [Accepted: 04/22/2011] [Indexed: 12/15/2022]
|
10
|
Löf C, Viitanen T, Sukumaran P, Törnquist K. TRPC2: Of Mice But Not Men. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2011; 704:125-34. [DOI: 10.1007/978-94-007-0265-3_6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
11
|
Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010; 151:5124-35. [PMID: 20861237 PMCID: PMC2954724 DOI: 10.1210/en.2010-0420] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Alterations in sphingolipid metabolism have been shown to contribute to the development of endocrine resistance and breast cancer tumor survival. Sphingosine kinase (SK), in particular, is overexpressed in breast cancer and is a promising target for breast cancer drug development. In this study, we used the novel SK inhibitor ABC294640 as a tool to explore the relationship between SK and estrogen (E2) receptor (ER) signaling in breast cancer cells. Treatment with ABC294640 decreased E2-stimulated ERE-luciferase activity in both MCF-7 and ER-transfected HEK293 cells. Furthermore, the inhibitor reduced E2-mediated transcription of the ER-regulated genes progesterone receptor and SDF-1. Competitive receptor-binding assays revealed that ABC294640 binds in the antagonist ligand-binding domain of the ER, acting as a partial antagonist similar to tamoxifen. Finally, treatment with ABC294640 inhibited ER-positive breast cancer tumor formation in vivo. After 15 d of treatment with ABC294640, tumor volume was reduced by 68.4% (P < 0.05; n = 5) compared with control tumors, with no marked weight loss or illness. Taken together, these results provide strong evidence that this novel SK inhibitor, which had not previously been known to interact with E2 signaling pathways, has therapeutic potential in treating ER-positive breast cancer via inhibition of both SK and ER signaling.
Collapse
Affiliation(s)
- James W Antoon
- Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Siow DL, Anderson CD, Berdyshev EV, Skobeleva A, Pitson SM, Wattenberg BW. Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate. J Lipid Res 2010; 51:2546-59. [PMID: 20386061 PMCID: PMC2918438 DOI: 10.1194/jlr.m004374] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2009] [Revised: 04/11/2010] [Indexed: 02/05/2023] Open
Abstract
Sphingosine kinase 1 (SK1) produces sphingosine-1-phosphate (S1P), a potent signaling lipid. The subcellular localization of SK1 can dictate its signaling function. Here, we use artificial targeting of SK1 to either the plasma membrane (PM) or the endoplasmic reticulum (ER) to test the effects of compartmentalization of SK1 on substrate utilization and downstream metabolism of S1P. Expression of untargeted or ER-targeted SK1, but surprisingly not PM-targeted SK1, results in a dramatic increase in the phosphorylation of dihydrosphingosine, a metabolic precursor in de novo ceramide synthesis. Conversely, knockdown of endogenous SK1 diminishes both dihydrosphingosine-1-phosphate and S1P levels. We tested the effects of SK1 localization on degradation of S1P by depletion of the ER-localized S1P phosphatases and lyase. Remarkably, S1P produced at the PM was degraded to the same extent as that produced in the ER. This indicates that there is an efficient mechanism for the transport of S1P from the PM to the ER. In acute labeling experiments, we find that S1P degradation is primarily driven by lyase cleavage of S1P. Counterintuitively, when S1P-specific phosphatases are depleted, acute labeling of S1P is significantly reduced, indicative of a phosphatase-dependent recycling process. We conclude that the localization of SK1 influences the substrate pools that it has access to and that S1P can rapidly translocate from the site where it is synthesized to other intracellular sites.
Collapse
Affiliation(s)
- Deanna L. Siow
- Departments of Biochemistry and Molecular Biology, School of Medicine, University of Louisville, Louisville, KY
- Departments of Brown Cancer Center, School of Medicine, University of Louisville, Louisville, KY
| | - Charles D. Anderson
- Departments of Brown Cancer Center, School of Medicine, University of Louisville, Louisville, KY
| | - Evgeny V. Berdyshev
- Biological Sciences Division, Department of Medicine, University of Chicago, Chicago, IL
| | - Anastasia Skobeleva
- Biological Sciences Division, Department of Medicine, University of Chicago, Chicago, IL
| | - Stuart M. Pitson
- Centre for Cancer Biology, SA Pathology, Frome Road, Adelaide, Australia
- School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia
| | - Binks W. Wattenberg
- Departments of Biochemistry and Molecular Biology, School of Medicine, University of Louisville, Louisville, KY
- Departments of Brown Cancer Center, School of Medicine, University of Louisville, Louisville, KY
- Departments of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY
| |
Collapse
|